A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
SARS-CoV-2, the coronavirus disease-2019 (COVID-19), and the cause of the pandemic is extremely contagious among people and has spread around the world. Antivirals, immunomodulators, and other medications, such as antibiotics, stem cells, and plasma therapy, have all been utilized in the treatment o...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/12/11/1758 |
| _version_ | 1797467561284075520 |
|---|---|
| author | Fatma Haddad Ghadeer Dokmak Rafik Karaman |
| author_facet | Fatma Haddad Ghadeer Dokmak Rafik Karaman |
| author_sort | Fatma Haddad |
| collection | DOAJ |
| description | SARS-CoV-2, the coronavirus disease-2019 (COVID-19), and the cause of the pandemic is extremely contagious among people and has spread around the world. Antivirals, immunomodulators, and other medications, such as antibiotics, stem cells, and plasma therapy, have all been utilized in the treatment of COVID-19. To better understand the clinical efficacy of these agents and to aid in the selection of effective COVID-19 therapies in various countries, this study reviewed the effectiveness of the various pharmacologic agents that have been used for COVID-19 therapy globally by summarizing the clinical outcomes that have been obtained from the clinical trials published on each drug related to COVID-19 infection. The Food and Drug Administration (FDA) has authorized the use of remdesivir, paxlovid, molnupiravir, baricitinib, tixagevimab–cilgavimab, and bebtelovimab for the management of COVID-19. On the other hand, most research advises against using chloroquine and hydroxychloroquine to treat COVID-19 patients because they are not beneficial. Although the FDA has given emergency use authorization for some monoclonal antibodies, including bamlanivimab, etesevimab, casirivimab, and imdevimab for managing COVID-19, they are not currently approved for use because the Omicron variant has significantly reduced their in vitro susceptibility. In this study, we also included a wide range of alternative therapy strategies that effectively treat COVID-19 patients, although further randomized studies are necessary to support and assess their applicability. |
| first_indexed | 2024-03-09T18:55:24Z |
| format | Article |
| id | doaj.art-141a6b6255d041908da739952c404288 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T18:55:24Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-141a6b6255d041908da739952c4042882023-11-24T05:30:28ZengMDPI AGLife2075-17292022-11-011211175810.3390/life12111758A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19Fatma Haddad0Ghadeer Dokmak1Rafik Karaman2Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem 9103401, PalestinePharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem 9103401, PalestinePharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem 9103401, PalestineSARS-CoV-2, the coronavirus disease-2019 (COVID-19), and the cause of the pandemic is extremely contagious among people and has spread around the world. Antivirals, immunomodulators, and other medications, such as antibiotics, stem cells, and plasma therapy, have all been utilized in the treatment of COVID-19. To better understand the clinical efficacy of these agents and to aid in the selection of effective COVID-19 therapies in various countries, this study reviewed the effectiveness of the various pharmacologic agents that have been used for COVID-19 therapy globally by summarizing the clinical outcomes that have been obtained from the clinical trials published on each drug related to COVID-19 infection. The Food and Drug Administration (FDA) has authorized the use of remdesivir, paxlovid, molnupiravir, baricitinib, tixagevimab–cilgavimab, and bebtelovimab for the management of COVID-19. On the other hand, most research advises against using chloroquine and hydroxychloroquine to treat COVID-19 patients because they are not beneficial. Although the FDA has given emergency use authorization for some monoclonal antibodies, including bamlanivimab, etesevimab, casirivimab, and imdevimab for managing COVID-19, they are not currently approved for use because the Omicron variant has significantly reduced their in vitro susceptibility. In this study, we also included a wide range of alternative therapy strategies that effectively treat COVID-19 patients, although further randomized studies are necessary to support and assess their applicability.https://www.mdpi.com/2075-1729/12/11/1758COVID-19antiviralsSARS-CoV-2immunomodulatorsmonoclonal antibodies |
| spellingShingle | Fatma Haddad Ghadeer Dokmak Rafik Karaman A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19 Life COVID-19 antivirals SARS-CoV-2 immunomodulators monoclonal antibodies |
| title | A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19 |
| title_full | A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19 |
| title_fullStr | A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19 |
| title_full_unstemmed | A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19 |
| title_short | A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19 |
| title_sort | comprehensive review on the efficacy of several pharmacologic agents for the treatment of covid 19 |
| topic | COVID-19 antivirals SARS-CoV-2 immunomodulators monoclonal antibodies |
| url | https://www.mdpi.com/2075-1729/12/11/1758 |
| work_keys_str_mv | AT fatmahaddad acomprehensivereviewontheefficacyofseveralpharmacologicagentsforthetreatmentofcovid19 AT ghadeerdokmak acomprehensivereviewontheefficacyofseveralpharmacologicagentsforthetreatmentofcovid19 AT rafikkaraman acomprehensivereviewontheefficacyofseveralpharmacologicagentsforthetreatmentofcovid19 AT fatmahaddad comprehensivereviewontheefficacyofseveralpharmacologicagentsforthetreatmentofcovid19 AT ghadeerdokmak comprehensivereviewontheefficacyofseveralpharmacologicagentsforthetreatmentofcovid19 AT rafikkaraman comprehensivereviewontheefficacyofseveralpharmacologicagentsforthetreatmentofcovid19 |